6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 18 Sep 2024
- Reporting date
- 18 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,805 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 601-625 of 1,000 matching filings.
Per page
25
Current page
25
6-K
File 001-15170
JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA
- Filing date
- 17 Sep 2024
- Reporting date
- 17 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP
- Filing date
- 13 Sep 2024
- Reporting date
- 13 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Sep 2024
- Reporting date
- 12 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA
- Filing date
- 12 Sep 2024
- Reporting date
- 12 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 11 Sep 2024
- Reporting date
- 11 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
CHANGE OF REGISTERED OFFICE
- Filing date
- 11 Sep 2024
- Reporting date
- 11 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL
- Filing date
- 11 Sep 2024
- Reporting date
- 11 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS
- Filing date
- 09 Sep 2024
- Reporting date
- 09 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 06 Sep 2024
- Reporting date
- 06 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
POSITIVE PHASE III RESULTS FOR NUCALA IN COPD
- Filing date
- 06 Sep 2024
- Reporting date
- 06 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 03 Sep 2024
- Reporting date
- 03 Sep 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EMA APPROVAL ON AREXVY FOR 50-59 AT RISK
- Filing date
- 29 Aug 2024
- Reporting date
- 29 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP
- Filing date
- 28 Aug 2024
- Reporting date
- 28 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN
- Filing date
- 28 Aug 2024
- Reporting date
- 28 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 28 Aug 2024
- Reporting date
- 28 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 21 Aug 2024
- Reporting date
- 21 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 20 Aug 2024
- Reporting date
- 20 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION
- Filing date
- 20 Aug 2024
- Reporting date
- 20 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 16 Aug 2024
- Reporting date
- 16 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Aug 2024
- Reporting date
- 12 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 06 Aug 2024
- Reporting date
- 06 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA EXPANDS JEMPERLI APPROVAL
- Filing date
- 02 Aug 2024
- Reporting date
- 02 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Aug 2024
- Reporting date
- 01 Aug 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
2ND QUARTER RESULTS
- Filing date
- 31 Jul 2024
- Reporting date
- 31 Jul 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing